comparison of efficacy and complication of alteplase injection in acute ischemic stroke

Background and aim: alteplase is a thrombolytic drug that is produced by recombinant dna technology. tissue plasminogen activator enzyme which converts plasminogen to the active form of plasmin is also produced by the same technology; it causes fibrinolysis and clot dissolution. this study aimed to compare the efficacy and complications of alteplase injection in patients with acute ischemic stroke (ais) during the first 3 hours and 3-4.5 hours after the onset of symptoms. methods: in this study, patients with ais who were referred to golestan hospital of ahvaz city during 2018-2019 were selected. information was collected by a checklist. results: the results showed that the mean modified rankin scale (mrs) for 3 months and 6 months (p-value: 0.91 for 3 months and p-value: 0.80 for 6 months) and national institutes of health stroke scale (nihss) (p-value: 0.21) were not significantly different between both groups; statistically, no significant relationship was observed between them. the incidence of complications after treatment was almost similar, in both groups. conclusion: finally, it was concluded that complications and efficacy of rt-pa (alteplase) injection were not statistically different, between the two groups under study.